Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3974MR)

This product GTTS-WQ3974MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3974MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ920MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ10374MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ10225MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ13651MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ1080MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ5899MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ7153MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ166MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW